Skip to content
DataLookout
Menu

ELEGANCENCT06930859

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words
    • Trial sites expanded: 42 → 49 locations
    • Secondary endpoints: details revised at 6 of 7 entries
  2. Minor Study sites: 40 to 42v11
  3. Minor Study sites: 39 to 40v10
  4. Minor Start date: Dec 22, 2025 to Dec 3, 2025v9
  5. Minor Study sites: 37 to 39v8
  6. Minor Trial sites expanded: 34 → 37 locationsv7
  7. Minor Study sites: 29 to 34v6
  8. Minor Study sites: 27 to 29
    • Start date: Dec 3, 2025 to Dec 22, 2025
    v5
  9. Minor Study sites: 12 to 27v4
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 12
    • Start date changed from estimate of Dec 31, 2025 to Dec 3, 2025
    v3
  11. Notable Start date: Jul 31, 2025 to Dec 31, 2025
    • Enrollment target: 2883 to 2766
    • Study sites: 0 to 2
    • Primary and study completion dates: Jul 31, 2032 to Dec 31, 2032
    v2
  12. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Invasive breast cancer-free survival (IBCFS) according to the Standardized Definitions for Efficacy End Points (STEEP) criteria in a prospective cohort
Timeframe: Months 36, 48, 60

Secondary (7)

Invasive breast cancer-free survival in prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Invasive disease-free survival (IDFS) in prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Recurrence-free survival (RFS) in the prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Number of doses taken relative to the total planned doses of ribociclib %
Number of participants with AEs/SAEs including those of special interest, in patients receiving ribociclib
Show 2 moreShow less
Number of patients who discontinued ribociclib for any reason, due to any AE, and due to AEs of special interest
Patients' quality of life evaluated through a questionnaire

Arms and interventions

Ribociclib+AI

Patients with HR+ HER2- stage II-III breast cancer receiving adjuvant ribociclib plus AI (aromatase inhibitor)

Monotherapy AI

Patients with HR+ HER2- stage II-III breast cancer receiving adjuvant AI (aromatase inhibitor) monotherapy

Drugs: Ribociclib, Letrozole, Anastrozole

Sites

49 sites in 1 country